| Literature DB >> 29024776 |
Maria Vittoria Dieci1, Nina Radosevic-Robin2, Susan Fineberg3, Gert van den Eynden4, Nils Ternes5, Frederique Penault-Llorca6, Giancarlo Pruneri7, Timothy M D'Alfonso8, Sandra Demaria9, Carlos Castaneda10, Joselyn Sanchez10, Sunil Badve11, Stefan Michiels5, Veerle Bossuyt12, Federico Rojo13, Baljit Singh14, Torsten Nielsen15, Giuseppe Viale16, Seong-Rim Kim17, Stephen Hewitt18, Stephan Wienert19, Sybille Loibl20, David Rimm12, Fraser Symmans21, Carsten Denkert22, Sylvia Adams23, Sherene Loi24, Roberto Salgado25.
Abstract
Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.Entities:
Keywords: Breast cancer; Ductal carcinoma in situ; Neoadjuvant; Residual cancer burden; Residual disease; Tumor-infiltrating lymphocytes
Mesh：
Substances：
Year: 2017 PMID： 29024776 DOI： 10.1016/j.semcancer.2017.10.003
Source DB: PubMed Journal: Semin Cancer Biol ISSN： 1044-579X Impact factor: 15.707